title: Prior bowel resections, perianal disease, and a high initial Crohn's disease activity index are associated with corticosteroid resistance in active Crohn's disease.
abstract: OBJECTIVE
  Some patients with Crohn's disease (CD) do not respond to corticosteroid therapy. Furthermore, corticosteroids frequently cause side effects. Thus, predictive parameters for treatment refractoriness would be helpful for treatment decisions.
  
  
  METHODS
  A total of 300 patients with active CD (i.e., with a Crohn's Disease Activity Index [CDAI] >200) entered the study. Treatment started with 60-100 mg/day prednisolone equivalent, which was then tapered to 10-15 mg/day within 6 wk and maintained at that dose for another 4 wk. After 10 wk of treatment, response to steroids was defined by a CDAI <150, steroid resistance by a CDAI always > or =150 and steroid dependency by a relapse after dose reduction. Of 239 eligible patients, 196 were responders, 26 were steroid resistant, and 17 were steroid dependent.
  
  
  RESULTS
  Prior bowel resections, a high initial CDAI, and perianal disease were associated with steroid resistance. Of the steroid resistant patients 53.9% were bowel-resected compared to 20.4% of the responders (relative risk = 3.63; 95% CI = 1.79-7.36). Perianal disease was observed in 42.3% of steroid resistant patients versus 21.9% of responders (relative risk = 2.28; 95% CI = 1.12-4.66) and initial CDAI was 347+/-91 in resistant patients versus 301+/-81 in responders (p < 0.05). Parameters for steroid dependent patients were not significantly different from those of responders.
  
  
  CONCLUSIONS
  In this study (thus far the largest study for the evaluation of predictive factors for treatment refractoriness to corticosteroids in CD), only prior bowel resection, perianal disease, and a high initial CDAI were found to be predictive of resistance to steroid treatment.
authors.affiliation: Department of Internal Medicine I, University of Regensburg, Germany.
authors.forename: Cornelia M
authors.initials: CM
authors.lastname: Gelbmann
authors.forename: Gerhard
authors.initials: G
authors.lastname: Rogler
authors.forename: Volker
authors.initials: V
authors.lastname: Gross
authors.forename: Michael
authors.initials: M
authors.lastname: Gierend
authors.forename: Nicole
authors.initials: N
authors.lastname: Bregenzer
authors.forename: Tilo
authors.initials: T
authors.lastname: Andus
authors.forename: Jürgen
authors.initials: J
authors.lastname: Schölmerich
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D001004:Anus Diseases / Q000150:complications*; D003251:Constriction, Pathologic; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery*; D004311:Double-Blind Method; D004351:Drug Resistance; D005260:Female; D005544:Forecasting; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007410:Intestinal Diseases / Q000150:complications; D007422:Intestines / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D011446:Prospective Studies; D012003:Rectal Fistula / Q000150:complications; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D005938:Glucocorticoids; D011239:Prednisolone